Sustained monocyte activation in clinical remission of systemic vasculitis.

Abstract	Monocytes have been shown to be activated in ANCA-positive systemic vasculitis, but their state of activation in clinical remission is unknown.Fifteen patients with a new diagnosis of systemic vasculitis were included in the study. Blood samples were analysed at diagnosis and at clinical remission after three to six months. The expression of adhesion molecules (CD62L and CD11b) on monocytes and the serum concentration of the endothelium activation factor VEGF and the chemokine MIP-1alpha were determined.We demonstrate an increased expression of CD11b on monocytes from patients with acute vasculitis that is sustained in clinical remission. The increased state of activation in clinical remission was accompanied by a decrease in VEGF and MIP-1alpha levels. This generates the intriguing question whether a treatment targeted to normalize monocyte activation in clinical remission would have an impact on relapse rate and outcome in this group of patients with high risk of systemic and renal complications.
Authors	Agneta Wikman, Joachim Lundahl, Stefan H Jacobson
Journal	Inflammation (Inflammation) Vol. 31 Issue 6 Pg. 384-90 (Dec 2008) ISSN: 0360-3997 [Print] United States
PMID	18846416 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References	Antibodies, Antineutrophil Cytoplasmic CCL3 protein, human CD11b Antigen Chemokine CCL3 ITGAM protein, human Immunosuppressive Agents VEGFA protein, human Vascular Endothelial Growth Factor A L-Selectin
Topics	Adult Aged Antibodies, Antineutrophil Cytoplasmic (blood) CD11b Antigen (blood) Case-Control Studies Chemokine CCL3 (blood) Chemotaxis, Leukocyte (drug effects) Female Humans Immunosuppressive Agents (therapeutic use) Kidney Diseases (drug therapy, immunology) L-Selectin (blood) Male Middle Aged Monocytes (drug effects, immunology) Prospective Studies Remission Induction Time Factors Treatment Outcome Vascular Endothelial Growth Factor A (blood) Vasculitis (drug therapy, immunology) Young Adult

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!